Again, I'll answer in English.
If you look at the accord that was done in around 1989 with the pharmaceutical industry, they promised to move us up to 10% of the revenues we invested in R and D, which would still be about half of the OECD average. They hit it for a few years, but most of it was in clinical research. Clinical research means basically funding doctors to give it to patients. It's important, but it's not building an innovation system, because there's no knowledge to leave behind. They invested about 20% into actual or what I would call real R and D, and we're now back to the old levels.
If the IP system had been driving the investment decisions, that wouldn't have happened—it was all the other policy. So giving them more is not going to bring them back. They're restructuring anyway. The reason they're pulling out of Canada has nothing to do with Canada; it has to do with them moving out of R and D and going more to biotechnologies and consolidating. We can triple our patent rights and it's not going to have a marked increase, at least on an economic basis. Whether it would on the basis of you scratch my back and I'll scratch yours, I don't know, but in terms of economics, it will not have an impact.